posted on 2013-06-07, 00:00authored bySock-Hwee Tan, Abidali Mohamedali, Amit Kapur, Mark S. Baker
Human plasma arguably represents
the most comprehensive version
of the human proteome. Despite its immense theoretical discovery potential,
plasma has many high and medium abundance proteins that mask low abundance
protein disease biomarkers of relevance, making the discovery of novel
diagnostic markers particularly difficult. Some form of protein depletion
and/or fractionation is essential in order to detect markers of low
abundance. Here, we describe a “proof of concept” two-pronged
approach to immunodeplete abundant proteins from human plasma. The
method, called API (Abundant Protein Immunodepletion), involves the
fractionation of plasma using dual ion exchange columns (protein repetitive
orthogonal offline fractionation (PROOF)) to simplify the proteome,
the production of polyclonal IgY against each fraction and finally
using the purified antibodies in a immunodepletion column. We explored
the use of this product for immunodepletion of human plasma and identified
a total of 165 nonredundant proteins after depletion. Of these, 38
proteins that were not previously identified in nondepleted plasma
were now detected. It is envisaged that further optimization of the
method as well as its cyclic implementation (by reinjecting depleted
plasma into chickens for second round of antibody production) can
make this technology highly robust, extremely cost-effective, and
ideal for high throughput biomarker discovery.